Epoetin alfa for chemotherapy-induced anemia: Assessment of two equivalent dosing regimens

Community Oncology

Volumn 4, Issue 3, 2007, Pages 129-135

  Policarpo, Gina D ^a   Henry, David H ^b  

^a Pennsylvania Oncology Hematology Associates   (United States)

^b PENNSYLVANIA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HEMOGLOBIN; IRON; NAVELBINE; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE;

ADVANCED CANCER; ANEMIA; BLOOD TRANSFUSION; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG WITHDRAWAL; FEVER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; NAUSEA; NEUTROPENIA; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 34147169430     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70071-7     Document Type: Conference Paper

References (17)

1. Rodgers GM, Cella D, Chesney C, et al. National Comprehensive Cancer Network Cancer- and treatment-related anemia. Clinical practice guidelines in oncology - v.2.2006. Available at: www.nccn.org. Accessed June 28, 2006.
2. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-1634.
3. Bohlius J, Weingart O, Trelle S, Engert A. Cancer-related anemia and recombinant human erythropoietin - an updated overview. Nat Clin Pract Oncol 2006;3:152-164.
4. Mohandas K, Aledort L. Transfusion requirements, risks, and costs for patients with malignancy. Transfusion 1995;35:427-430.
5. Procrit (epoetin alfa) prescribing information. Raritan, NJ: Ortho Biotech Products, LP; 2006.
6. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002;100:2303-2320.
7. Case DC Jr, Bukowski RM, Carey RW, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993:85:801-806.
8. Henry DH, Brooks BJ Jr, Case DC Jr, et al. Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J (Sci Am) 1995;1:252-260.
9. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S, for the Procrit Study Group. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997;15:1218-1234.
10. Demetri GD, Kris M, Wade J, Degos L, Cella D, for the Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998;16:3412-3425.
11. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-2617.
12. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-2882.
13. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003;98:1072-1079.
14. Glaspy J, Degos L, Dicato M, Demetri GD. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. Oncologist 2002;7:126-135.
15. Waltzman R, Xie J, Yektashenas B, Williams D. Epoetin alfa 40,000 units once weekly vs darbepoetin 200 mcg every 2 weeks in anemic elderly patients with cancer receiving chemotherapy [abstract]. Poster presented at the Geriatric Oncology Consortium/Advancing Cancer Care in the Elderly 2005 Annual Meeting; September 15-17, 2005; Washington, DC.
16. Henry DH, Xie J, Szczudlo T, Wilhelm FE. Epoetin alfa (EPO) 80,000 U Q2W vs 40,000 U QW in chemotherapy-induced anemia (CIA): elderly subset from a randomized clinical trial [abstract]. Poster presented at the Geriatric Oncology Consortium/Advancing Cancer Care in the Elderly 2006 Annual Meeting; September 14-16, 2006; Washington, DC.
17. Dale DC. Poor prognosis in elderly patients with cancer: the role of bias and undertreatment. J Support Oncol 2003;1(4 suppl 2):11-17.